PGAP2

Across TCGA pan-cancer cohorts, PGAP2 mass-spec protein is linked to patient survival in 1 of 34 cancer types, making it a survival-associated PGAP2 data layer compared with 21 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher PGAP2 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated PGAP2 expression acts as an unfavorable survival marker, although some lineages such as LUAD show a favorable association.

LUAD are the cancer types where PGAP2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Tertile	All	0.916	0.492	.024	8	view →

Pink = unfavorable, green = favorable. Showing the 1 strongest of 1 lineages.

PGAP2–LUAD (OS)

Open the LUAD breakdown →